DAVANAT

Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic liver diseases and cancer by targeting galectin proteins. The company's lead candidate, belapectin (formerly GR-MD-02), is currently in Phase 3 clinical trials for the treatment of liver cirrhosis associated with nonalcoholic steatohepatitis (NASH). Their earlier lead compound, Davanat (GM-CT-01), was developed as a galectin-targeting carbohydrate polymer designed to enhance the efficacy and reduce the toxicity of chemotherapy agents like 5-fluorouracil. Galectin Therapeutics leverages its proprietary carbohydrate chemistry platform to create complex polysaccharide drugs that inhibit galectin-3, a protein heavily involved in fibrosis and tumor immune evasion.